FULGENT GENETICS INC. overview

The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT ). The investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices. Fulgent engages in the provision of gene testing and sequencing solutions. The Company offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. On August...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Fulgent released its financial results for the second quarter of 2022 on August 4, 2022....

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT ) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Fulgent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or “the Company”) (NASDAQ: FLGT ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Fulgent released its financial results for the second quarter of 2022 on August 4, 2022. As...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Fulgent released its financial results for the second quarter of 2022 on August 4, 2022....

Law Offices of Howard G. Smith announces an investigation on behalf of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT ) investors concerning the Company’s possible violations of federal securities laws. On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC is conducting an investigation into certain Exchange Act reports for 2018 through the first quarter of 2020. This comes after the Company received a civil...

The Law Offices of Frank R. Cruz announces an investigation of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT ) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC is conducting an investigation into certain Exchange Act reports for 2018 through the...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Results: Revenue of $125.3 million, versus $153.6 million in Q2 2021 Billable tests delivered over 1.3 million, versus 1.6 million in Q2 2021 Core...